Form 4: Tarsus Pharmaceuticals CEO Bobak Azamian Reports Stock Transactions
SEC Form 4 Filing
Bobak Azamian, President/CEO and Board Chair of Tarsus Pharmaceuticals, reports the acquisition and disposal of common stock and restricted stock units.
Summary
- On March 15, 2024, Bobak Azamian acquired 28,274 shares of common stock through the settlement of vested Restricted Stock Units (RSUs).
- Also on March 15, 2024, 11,299 RSUs granted on March 9, 2022, vested, and 16,975 RSUs granted on March 8, 2023, vested.
- On March 18, 2024, Azamian sold 10,415 shares of common stock at a price of $30.6 per share to cover tax withholding obligations related to the vesting of RSUs.
- Following these transactions, Azamian directly owns 26,456 shares of common stock and indirectly owns 830,106 shares through the Bobak Azamian Living Trust established April 16, 2018.
- Azamian also directly owns 22,599 RSUs granted on March 9, 2022, and 50,925 RSUs granted on March 8, 2023.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The transactions are routine and related to executive compensation and tax obligations. There's no indication of significant concern or excitement.
Positives
- The vesting of RSUs indicates that performance milestones have been met, which is generally a positive sign.
Negatives
- The sale of 10,415 shares, even if for tax purposes, could be perceived negatively by some investors, although it's a common practice.
Risks
- While the sale of shares was to cover taxes, large insider sales can sometimes create downward pressure on the stock price.
Industry Context
Insider transactions are routinely monitored by investors as they can provide insights into management's perspective on the company's valuation and future prospects. The sale to cover taxes is a common practice.
Comparison to Industry Standards
- Monitoring insider transactions is a standard practice in the pharmaceutical industry, similar to how investors track executive compensation and stock ownership at companies like AbbVie, Pfizer, and Amgen.
- The vesting schedule of the RSUs is typical for executive compensation packages in the biotech sector, aligning with long-term company performance.
Stakeholder Impact
- The transactions are unlikely to have a significant impact on stakeholders, as they are related to standard executive compensation practices.
Key Dates
| Date | Description |
|---|---|
| April 16, 2018 | Date the Bobak Azamian Living Trust was established. |
| March 9, 2022 | Date of RSU grant, vesting in installments until March 15, 2026. |
| March 8, 2023 | Date of RSU grant, vesting in installments until March 15, 2027. |
| March 15, 2024 | Date of RSU settlement and acquisition of common stock. |
| March 18, 2024 | Date of common stock sale for tax obligations. |
| March 19, 2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.